Myopia Control With a Innovative Spectacle Lens - A Cessation Study

N/AActive Not RecruitingNCT06884527

Essilor International91 enrolled

Overview

The purpose of this study is to quantify myopic progression following cessation of a innovative spectacle lenses after 3 years' use.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Myopia Progressing

Interventions

Single Vision Lens to A innovative spectacle lensDEVICE

Participants in this arm are from the test group of the previous clinical trial (NCT05174780), where they wore the innovative spectacle lenses for three years. They will now wear single vision lenses for 12 months.

Single Vision Lens to A innovative spectacle lensDEVICE

Participants in this arm are from the control group of the previous clinical trial (NCT05174780), where they wore the single vision spectacle lenses for three years. They will now wear single vision lenses for another 12 months.

Eligibility

Sex: ALLMin age: 9 YearsMax age: 15 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Existing subjects from the NCT05174780 clinical study. * Ability to comply with study procedures. * Informed consent of parent/guardian and assent of subject. Exclusion Criteria: * Current ocular infection, inflammation, or irritation likely to affect vision.

Locations (5)

Illinois College of Optometry

Chicago, Illinois, United States

Kannarr Eye Care

Pittsburg, Kansas, United States

New England College of Optometry

Boston, Massachusetts, United States

SUNY College of Optometry

New York, New York, United States

Outcomes

Primary Outcomes

Change in cycloplegic spherical equivalent refraction from baseline

Time frame: 0 - 12 months

Change in Axial Length from baseline

Time frame: 0 - 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.